Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05271487
Other study ID # CB_Acne_01
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 7, 2022
Est. completion date March 1, 2023

Study information

Verified date February 2022
Source Integrative Skin Science and Research
Contact Jessica Maloh
Phone 9167502463
Email jessica@integrativeskinresearch.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date March 1, 2023
Est. primary completion date July 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 45 Years
Eligibility Inclusion Criteria: - Subjects 15 years of age until 45 years of age. - The presence of mild to moderate acne based on investigator global assessment. Exclusion Criteria: - The presence of severe acne as noted by the investigator global assessment. - Those with a nut allergy. - Those who are unwilling to discontinue oral probiotic-based supplementation to meet the washout criteria prior to enrolling. - Those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide to meet the washout criteria prior to enrolling. - Individuals who are unwilling to discontinue vitamin E containing supplements during the washout and intervention. - Individuals who have been on an oral antibiotic for acne within the previous 1 month. - Individuals who are pregnant or breastfeeding. - Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study. - Oral supplementation that has nuts in it. - Use of isotretinoin within the three months prior to joining the study. - Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Multi-Step Botanical Skin Care Regimen
The intervention includes 7 different topical products: Cleanser Toner Oil Control Cream Exfoliating Facial Scrub Clay Mask Acne Spot Treatment Body Scrub

Locations

Country Name City State
United States Integrative Skin Science and Research Sacramento California

Sponsors (2)

Lead Sponsor Collaborator
Integrative Skin Science and Research Codex Beauty Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total lesion count Number of of inflammatory lesions, and open and closed comedones 8 weeks
Secondary Inflammatory lesion count Number of inflammatory lesions 4 weeks
Secondary Inflammatory lesion count Number of inflammatory lesions 8 weeks
Secondary Non-inflammatory lesion count Number of open and closed comedones 4 weeks
Secondary Non-inflammatory lesion count Number of open and closed comedones 8 weeks
Secondary Investigator global assessment (IGA) of acne Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne 4 weeks
Secondary Investigator global assessment (IGA) of acne Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne 8 weeks
Secondary Sebum excretion Measure of skin sebum via sebumeter 4 weeks
Secondary Sebum excretion Measure of skin sebum via sebumeter 8 weeks
Secondary Gut microbiome assessment Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample 4 weeks
Secondary Gut microbiome assessment Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample 8 weeks
Secondary Skin microbiome diversity Shift in Shannon diversity of the skin microbiome 4 weeks
Secondary Skin microbiome diversity Shift in Shannon diversity of the skin microbiome 8 weeks
Secondary Positive and Negative Affect Schedule (PANAS-SF) Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect 4 weeks
Secondary Positive and Negative Affect Schedule (PANAS-SF) Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect 8 weeks
Secondary Diurnal Cortisol Slope 4 salivary cortisol collections to assess diurnal slope 4 weeks
Secondary Diurnal Cortisol Slope 4 salivary cortisol collections to assess diurnal slope 8 weeks
Secondary Salivary Sex Hormone Levels 1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS 4 weeks
Secondary Salivary Sex Hormone Levels 1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04321070 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Phase 1
Recruiting NCT05755256 - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne Phase 2
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT01445301 - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects Phase 3
Completed NCT03303170 - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris N/A
Completed NCT04698239 - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions. N/A
Completed NCT02886715 - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris Phase 3
Terminated NCT02924428 - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris N/A
Completed NCT02709902 - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris Phase 1
Not yet recruiting NCT02491060 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Not yet recruiting NCT02535871 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Not yet recruiting NCT02525822 - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris Phase 2
Completed NCT02250430 - A Phase 1 Study Assessing Local Cutaneous Effects of SB204 Phase 1
Completed NCT02913001 - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne N/A
Completed NCT01694810 - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers Phase 1
Completed NCT01769664 - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris Phase 1
Completed NCT01727440 - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment N/A
Completed NCT01194375 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris Phase 2
Completed NCT02524665 - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Phase 4
Completed NCT01706250 - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Phase 4